Becton Dickinson sees FY25 revenue ~$21.8B, consensus $21.86B

Sees full year preliminary unaudited revenue of approximately $21.8B, which represents an estimated increase of approximately 8.2% on a reported basis, 7.7% on an adjusted currency-neutral basis and 2.9% on an organic basis. CEO Polen continued, “While we continue to navigate a dynamic macro environment that had a greater than anticipated impact this quarter in areas we have been closely monitoring, specifically Pharmaceutical Systems vaccines and Biosciences academic and government research, we delivered strong growth across multiple areas including the BD Interventional segment, Advanced Patient Monitoring and Medication Delivery Solutions. Looking ahead, we continue to execute on our strategy and are taking further action to unlock value, including investments in areas of opportunity to drive growth and continued margin momentum. I look forward to sharing more on our New BD strategy and expectations for fiscal 2026 on our upcoming earnings call.”